NICE Draft Guidance: Rejects Keytruda In Head & Neck Cancer, Xospata In AML

But Positive On Lynparza And Ibrance In Certain Settings

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.